Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is well-positioned for success due to a strong initial launch of their drug FILSPARI, significant upcoming catalysts with potential for further label expansion, and strong support from key opinion leaders. Financially, the company has a solid cash balance and continues to de-risk their commercial story. However, there are potential risks for the company including the potential for delays or setbacks in commercialization and the possibility of additional capital raises. Overall, the fundamental outlook for Travere Therapeutics is positive and presents a strong opportunity for growth in the rare disease market.

Bears say

Travere Therapeutics is experiencing seasonal headwinds in their 1Q26 total revenue, missing both consensus and Wall Street estimates. With other agents entering the IgAN treatment landscape and an expected mid-20s growth rate, there is potential for positive signals. However, with the management's expectation of nephrologists waiting for patients' next scheduled visit to prescribe the drug, there may be a delay in treatment and potential lower revenue for Filspari in the near term. Additionally, while the recently approved expanded indication for Filspari in FSGS could greatly increase the addressable patient population, it may take some time for these patients to begin treatment, potentially slowing overall revenue growth for the company.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.